Journal of Jilin University(Medicine Edition) ›› 2021, Vol. 47 ›› Issue (2): 344-351.doi: 10.13481/j.1671-587X.20210213

• Research in basic medicine • Previous Articles     Next Articles

Inhibitory effect of new VEGF monoclonal antibody combined with all-trans retinoic acid on proliferation of breast cancer MCF-7 cells

Haoxuan TANG1,2,Nanfeng MENG1,2,Meiling DU1,2,Wei WANG1,2,Tao HE1,2()   

  1. 1.Graduate School of Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou 014010,China
    2.Department of General Surgery,First Affiliated Hospital,Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou 014010,China
  • Received:2020-07-23 Online:2021-03-28 Published:2021-03-25
  • Contact: Tao HE E-mail:manfred_ht@163.com

Abstract: Objective

To explore the effects of new vascular endothelial growth factor (VEGF) monoclonal antibody, all-trans retinoic acid (ATRA), new VEGF monoclonal antibody combined with ATRA on the breast cancer MCF-7 cells, and to provide a new clinical approach for the treatment of breast cancer.

Methods

The breast cancer MCF-7 cells were divided into control group (without any treatment), VEGF antibody group (20 mg·L-1 VEGF antibody), ATRA group (10 μmol·L-1 ATRA) and VEGF antibody + ATRA group (20 mg·L-1 VEGF antibody+10 μmol·L-1 ATRA), each with 5 replicates. After the MCF-7 cells were treated with different drugs for 48 h,the VEGF antibody concentration was determined by ELISA, the proliferation rate of MCF-7 cells was determined by MTT assay, the apoptotic rate of MCF-7 cells was determined by flow cytometry, and the expression levels of B cell lymphoma-2(Bcl-2),Bcl-2 associated X protein( Bax) and nuclear factor-κB(NF-κB) proteins in the MCF-7 cells were determined by Western blotting method.

Results

The ELISA results showed that the new human recombinant VEGF monoclonal antibody had good quality compared with positive antibody control and its concentration was 200 μg·L-1.The MTT results showed that the prolifenation rate of MCF-7 cells in VEGF antibody + ATRA group was decreased obviously compared with control group (P<0.01).The flow cytometry results showed that compared with control group,VEGF antibody group and ATRA group, the apoptotic rate of MCF-7 cells in VEGF antibody + ATRA group was significantly increased (P<0.01);compared with control group,the apoptotic rates of MCF-7 cells in VEGF antibody group and ATRA group were significantly increased(P<0.01);compared with VEGF antibody group,the apototic rate of MCF-7 cells in ATRA group was significantly increased(P<0.01). The results of Western blotting method showed that compared with control group, VEGF antibody group and ATRA group, the expression level of Bcl-2 protein in VEGF antibody+ATRA group was significantly decreased (P<0.05);compared with control group and VEGF antibody group, the expression level of NF-κB protein in MCF-7 cells in ATRA group was decreased (P<0.05 or P<0.01), and the expression level of Bax protein was increased (P<0.01).

Conclusion

The new VEGF monoclonal antibody and ATRA can inhibit the cell proliferation and promote apoptosis of breast cancer MCF-7 cells, and the effect of their combination is significantly better than each drug used alone.

Key words: breast neoplasms, vascular endothelial growth factor, monoclonal antibody, all-trans retinoic acid, apoptosis, proliferation

CLC Number: 

  • R737.9